Cytosorbents Corporation
CTSO
$0.8903
-$0.0228-2.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.62M | 8.73M | 6.52M | 9.39M | 8.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.62M | 8.73M | 6.52M | 9.39M | 8.84M |
| Cost of Revenue | 2.80M | 2.52M | -247.90K | 4.11M | 2.34M |
| Gross Profit | 6.81M | 6.21M | 6.77M | 5.28M | 6.50M |
| SG&A Expenses | 9.17M | 8.43M | 9.83M | 7.76M | 8.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.23M | 12.61M | 10.88M | 13.72M | 12.41M |
| Operating Income | -3.62M | -3.89M | -4.36M | -4.33M | -3.57M |
| Income Before Tax | 1.95M | -1.48M | -9.57M | -2.33M | -4.29M |
| Income Tax Expenses | -- | -- | -1.69M | -- | -- |
| Earnings from Continuing Operations | 1.95M | -1.48M | -7.88M | -2.33M | -4.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.95M | -1.48M | -7.88M | -2.33M | -4.29M |
| EBIT | -3.62M | -3.89M | -4.36M | -4.33M | -3.57M |
| EBITDA | -3.21M | -3.52M | -3.97M | -3.95M | -3.17M |
| EPS Basic | 0.03 | -0.02 | -0.14 | -0.04 | -0.08 |
| Normalized Basic EPS | 0.02 | -0.02 | -0.11 | -0.03 | -0.05 |
| EPS Diluted | 0.03 | -0.02 | -0.14 | -0.04 | -0.08 |
| Normalized Diluted EPS | 0.02 | -0.02 | -0.11 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 62.61M | 60.73M | 54.71M | 54.45M | 54.31M |
| Average Diluted Shares Outstanding | 67.17M | 60.73M | 54.71M | 54.45M | 54.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |